AstraZeneca Q1 Results Beat Expectations on Strong Drug Demand
AstraZeneca reported strong first-quarter results, with revenue and core earnings exceeding expectations. Growth was driven by robust demand for its oncology and rare-disease treatments, which delivered double-digit sales gains across key product lines.
Revenue Growth Surpasses Analyst Forecasts
The company generated $15.29 billion in revenue, up from $13.59 billion in the same period last year and above the $14.94 billion consensus estimate. On a constant currency basis, revenue increased 8% year-over-year, highlighting steady underlying growth.
Oncology Segment Leads Performance
Sales from oncology treatments rose 16% year-on-year to $6.8 billion, accounting for approximately 44% of total group revenue. This segment continues to be the primary driver of AstraZeneca’s overall performance.
CEO Highlights Strong Execution and Future Pipeline
Chief Executive Officer Pascal Soriot emphasized the company’s strong start to 2026, noting that revenue exceeded $15 billion due to consistent commercial execution.
He also highlighted ongoing investments in product launches and clinical development, reinforcing confidence in the company’s long-term growth strategy through 2030 and beyond.
Key Drugs Deliver Strong Sales Growth
Several flagship treatments contributed significantly to the quarterly performance:
- Imfinzi, used in bladder and lung cancer, saw revenue rise 30% to $1.7 billion
- Tagrisso, a lung cancer therapy, increased 5% to $1.8 billion
- Enhertu, targeting breast and gastric cancers, surged 34% to $831 million
Profitability Metrics Improve
Core earnings per share (EPS), which excludes one-off items, reached $2.58, exceeding analyst expectations of $2.54 and rising 5% year-on-year at constant currency.
Core operating profit increased 12% to $4.25 billion, while net profit climbed to $3.08 billion, up from $2.92 billion a year earlier.
Full-Year Outlook Remains Positive
AstraZeneca reaffirmed its full-year guidance, projecting mid-to-high single-digit revenue growth and low double-digit growth in core EPS, reflecting continued confidence in demand for its key therapies and pipeline expansion.
